Blinatumomab is administered via continuous intravenous infusion, typically over a period of 28 days, followed by a 14-day rest period. This cycle may be repeated depending on the patient's response to treatment and overall health status. Due to the complexity of its administration, treatment usually occurs in a specialized healthcare setting.
